Current Cancer Clinical Trials List

Cancer clinical trials lead to new treatments and cures. That’s why we do what we do every day.

Below is an up-to-date list of our cancer clinical trials currently underway. CAN focuses primarily on Phase II and Phase III trials, conducting further research on treatments that have already shown promise during Phase I trials. If you are a cancer patient interested in participating in a clinical trial, please visit our Patient section for more information.

Filter
Sending

Clinical Trials

Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Disease Site: Cancer Control
Protocol Number: A221602
Status: OPEN
Key Eligibility: No prior chemo; sched to rcv HEC (cisplatin regimen or AC); no naus/vom < 24hrs prior to reg
Description:
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Disease Site: Cancer Control
Protocol Number: A011401
Status: OPEN
Key Eligibility: Invasive breast ca; HER2-Neg; no T1-2, N1mi
Description:
A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial

Disease Site: Cancer Control
Protocol Number: A011502
Status: OPEN
Key Eligibility: Stage II or III w/I 1 year of dx and free of recurrence
Description:
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

Disease Site: Melanoma
Protocol Number: S1607
Status: OPEN
Key Eligibility: Stage IV or unresectable stage III; must have prior anti-PD-1 or anti-PD-L1 tx;
Description:
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Disease Site: Lung
Protocol Number: A151216
Status: OPEN
Key Eligibility: Suspected resectable or completely resected stage IB, II, or IIIA NSCLC; no adjuvant tx
Description:
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Disease Site: Lung
Protocol Number: EA5142
Status: OPEN
Key Eligibility: Complete surgical resection of stage IB, II or IIIA NSCLC; non-squamous must be EGFR and ALK wild-type; no prior immune checkpoint inhibitor
Description:

Requires participation in ALCHEMIST (A151216) trial

Phase II/III Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (NCT02154490) TRIAD Imaging

Disease Site: Lung
Protocol Number: S1400
Status: OPEN
Key Eligibility: Advanced Squamous NSCLC; Stage IIIB or Stage IV; one front-line platinum, metastatic chemo; progressive disease
Description:
Qualitative Interviews in Patients with Smoldering Multiple Myeloma and Patients with Multiple Myeloma

Disease Site: Hematology
Protocol Number: EVA-21335
Status: OPEN
Key Eligibility: SMM <5 years w/measurable disease; MM w/I last 2 years w/prior SMM dx; dx at least 30 days prior to screening; no MM requiring tx
Description:
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or Hi-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

Disease Site: Hematology
Protocol Number: MOST (INCB-MA-MF-401)
Status: OPEN
Key Eligibility: MF – PPV-MF or PET-MF; low or intermediate risk ET - >60 OR history of thromboembolic events OR currently receiving ET-directed tx
Description:
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck

Disease Site: Head/Neck
Protocol Number: EA3132
Status: OPEN
Key Eligibility: Squamous cell; stage III or IVA; total resection of primary tumor; no prev radiation that will overlap in current disease; no recurrent disease
Description:
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)

Disease Site: Genitourinary
Protocol Number: S1500
Status: Temp Suspended 12/5/18
Key Eligibility: Papillary, metastatic renal cell or locally advanced disease not amenable to resection; up to one prior systemic therapy for metastatic/locally advanced ok
Description:
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Disease Site: Breast
Protocol Number: B58
Status: OPEN
Key Eligibility: HR+, HER2-, early stage resected invasive brca – no mets; adjuvant; no stage IV (M1), stage IA, or lymph node negative brca
Description:

The following physicians are participating in this trial:
NHO: Avery, Midathada
SENCC: Dunder, Tilford, Green, Peterson, Berg

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Disease Site: Gastrointestinal
Protocol Number: GI-002
Status: OPEN
Key Eligibility: Stage II or III; adenocarcinoma only; no metastatic disease; no prior invasive rectal malignancy
Description:
A disease registry for patients with chronic lymphocytic leukemia

Disease Site: Hematology
Protocol Number: informCLL
Status: OPEN
Key Eligibility: CLL/SLL; initiating tx w/I 30 days of enrollment w/novel therapies; no dx of b-cell malignancies other than CLL/SLL
Description:
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma
Protocol Number: EA6141
Status: OPEN
Key Eligibility: Known BRAF; wild-type or mutated; prior adjuvant tx ok; no prior ipilimumab or PD-1/PD-L1 in adjuvant setting
Description:
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Disease Site: Melanoma
Protocol Number: EA6134
Status: OPEN
Key Eligibility: Unresectable stage III or IV disease; metastatic or unresectable, clearly progressive; BRAFV600E mutations; no previous CTLA4 or PD1 pathway blocking or BRAF/MEK inhibitor
Description:
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Disease Site: Breast
Protocol Number: NRG-BR003
Status: OPEN
Key Eligibility: pT1-3; pN0, pN1, pN2a-b; pN3a-b, HER2-, ER/PgR-, no T4, no met disease
Description:

RADIATION THERAPY FACILITY INVENTORY FORM REQUIRED TO BE SENT TO CTSU PRIOR TO ENROLLMENT. PLEASE SEND COPY TO MVCC OFFICE ONCE COMPLETE

Molecular Analysis for Therapy Choice (MATCH)

Disease Site: Cancer Control
Protocol Number: EAY131
Status: OPEN
Key Eligibility: Solid tumor or lymphoma that has progressed following at least 1 line of standard therapy. Matching biopsy results to specific drug therapy
Description:
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Disease Site: Lung
Protocol Number: A081105
Status: OPEN
Key Eligibility: Prev registration to A151216; EGF exon 19 deletion or L858R mutation; completely resected stage IB, II, or IIIA non-squamous w/neg margins
Description:
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Disease Site: Lung
Protocol Number: E4512
Status: OPEN
Key Eligibility: Complete resection of stage IB, II, or IIIA NSCLC; registration to ALCHEMIST-SCREEN (A151216); Positive for translocation or inversion events involving the ALK gene locus
Description:
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA ½ Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Disease Site: Breast
Protocol Number: B55
Status: OPEN
Key Eligibility: Non-metastatic triple negative; must have rcvd adjuvant therapy; documented BRCA 1 or 2 deleterious mutation; no prior PARP inhibitor
Description:
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Disease Site: Breast
Protocol Number: S1207
Status: OPEN
Key Eligibility: ER/PR, HER-2 negative invasive breast carcinoma; no metastatic disease; high risk
Description:
NSABP Patient Registry and Biospecimen Profiling Repository

Disease Site: Gastrointestinal
Protocol Number: MPR-1
Status: OPEN
Key Eligibility: Metastatic colorectal cancer; available block from primary tumor
Description:
Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Disease Site: Brain
Protocol Number: N0577
Status: OPEN
Key Eligibility: 1p/19q Co-deleted Anaplastic Glioma
Description: